BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12068373)

  • 1. Atypical 5' splice sites cause CFTR exon 9 to be vulnerable to skipping.
    Hefferon TW; Broackes-Carter FC; Harris A; Cutting GR
    Am J Hum Genet; 2002 Aug; 71(2):294-303. PubMed ID: 12068373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing.
    Zuccato E; Buratti E; Stuani C; Baralle FE; Pagani F
    J Biol Chem; 2004 Apr; 279(17):16980-8. PubMed ID: 14966131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9.
    Niksic M; Romano M; Buratti E; Pagani F; Baralle FE
    Hum Mol Genet; 1999 Dec; 8(13):2339-49. PubMed ID: 10556281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations.
    Dörk T; Fislage R; Neumann T; Wulf B; Tümmler B
    Hum Genet; 1994 Jan; 93(1):67-73. PubMed ID: 7505767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene.
    Aznarez I; Chan EM; Zielenski J; Blencowe BJ; Tsui LC
    Hum Mol Genet; 2003 Aug; 12(16):2031-40. PubMed ID: 12913074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon identity influences splicing induced by exonic variants and in silico prediction efficacy.
    Martin N; Bergougnoux A; Baatallah N; Chevalier B; Varilh J; Baux D; Costes B; Fanen P; Raynal C; Sermet-Gaudelus I; Girodon E; Taulan-Cadars M; Hinzpeter A
    J Cyst Fibros; 2021 May; 20(3):464-472. PubMed ID: 33341408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects.
    Fernandez Alanis E; Pinotti M; Dal Mas A; Balestra D; Cavallari N; Rogalska ME; Bernardi F; Pagani F
    Hum Mol Genet; 2012 Jun; 21(11):2389-98. PubMed ID: 22362925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative splicing of the ovine CFTR gene.
    Broackes-Carter FC; Williams SH; Wong PL; Mouchel N; Harris A
    Mamm Genome; 2003 Nov; 14(11):778-87. PubMed ID: 14722727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles.
    Steiner B; Truninger K; Sanz J; Schaller A; Gallati S
    Hum Mutat; 2004 Aug; 24(2):120-9. PubMed ID: 15241793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skipping of exon 9 of human CFTR in YAC-transgenic mice.
    Manson A; Huxley C
    Genomics; 2001 Oct; 77(3):127-34. PubMed ID: 11597137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How slow RNA polymerase II elongation favors alternative exon skipping.
    Dujardin G; Lafaille C; de la Mata M; Marasco LE; Muñoz MJ; Le Jossic-Corcos C; Corcos L; Kornblihtt AR
    Mol Cell; 2014 May; 54(4):683-90. PubMed ID: 24793692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined computational-experimental analyses of CFTR exon strength uncover predictability of exon-skipping level.
    Aissat A; de Becdelièvre A; Golmard L; Vasseur C; Costa C; Chaoui A; Martin N; Costes B; Goossens M; Girodon E; Fanen P; Hinzpeter A
    Hum Mutat; 2013 Jun; 34(6):873-81. PubMed ID: 23420618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element.
    Pagani F; Buratti E; Stuani C; Romano M; Zuccato E; Niksic M; Giglio L; Faraguna D; Baralle FE
    J Biol Chem; 2000 Jul; 275(28):21041-7. PubMed ID: 10766763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter architecture modulates CFTR exon 9 skipping.
    Pagani F; Stuani C; Zuccato E; Kornblihtt AR; Baralle FE
    J Biol Chem; 2003 Jan; 278(3):1511-7. PubMed ID: 12421814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In NF1, CFTR, PER3, CARS and SYT7, alternatively included exons show higher conservation of surrounding intron sequences than constitutive exons.
    Kaufmann D; Kenner O; Nurnberg P; Vogel W; Bartelt B
    Eur J Hum Genet; 2004 Feb; 12(2):139-49. PubMed ID: 14560314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splice site skipping in polyomavirus late pre-mRNA processing.
    Luo Y; Carmichael GG
    J Virol; 1991 Dec; 65(12):6637-44. PubMed ID: 1719232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.
    Aznarez I; Zielenski J; Rommens JM; Blencowe BJ; Tsui LC
    J Med Genet; 2007 May; 44(5):341-6. PubMed ID: 17475917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TDP43 depletion rescues aberrant CFTR exon 9 skipping.
    Ayala YM; Pagani F; Baralle FE
    FEBS Lett; 2006 Feb; 580(5):1339-44. PubMed ID: 16458894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation of pre-mRNA sequence elements in splice site selection.
    Dominski Z; Kole R
    Mol Cell Biol; 1992 May; 12(5):2108-14. PubMed ID: 1569943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.